Novavax appoints Charles W. Newton to Board, increasing size to nine members

NOVAVAX INC

Board expanded from 8 to 9 members; Charles W. Newton appointed as Class III director effective April 25, 2025.
Newton receives initial equity grant of 42,840 stock options and 28,560 RSUs ($525,000 grant-date fair value).
Annual equity grants valued at $350,000 will begin after the 2026 Q2 board meeting.
Board affirms Newton qualifies as independent under Nasdaq standards; no related-party transactions.
Standard indemnification agreement to be entered with Novavax.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Charles W. Newton

Class III director

NVAX · NOVAVAX INC

Effective: 2025-04-25
Filed: April 29, 2025, 7:59 PM ET

appointed Charles W. Newton. to the Board, effective on such date, to fill the resulting vacancy and to serve as a Class III director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Charles W. Newton was appointed as Class III director at NOVAVAX INC.

Action: appointed
Role: Class III director

Exact text from the filing

appointed Charles W. Newton. to the Board, effective on such date, to fill the resulting vacancy and to serve as a Class III director

View on SEC.gov

NOVAVAX INC filing history →

Source: SEC EDGAR

accession 0001104659-25-040656

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.